2025 Q4 -tulosraportti
54 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
31,90%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 500 | - | - | ||
| 656 | - | - | ||
| 2 251 | - | - | ||
| 2 645 | - | - | ||
| 4 044 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sittenNykode continues to deliver small, but important data points: In VB-C-03, 10 out of 10 evaluable patients in the 6 mg and 9 mg groups achieved an HPV16-specific immune response. This strengthens the impression that abi-suva not only looks good on paper, but actually awakens the immune system as a cancer vaccine should. At the same time, something important is happening in the market: biotech M&A is clearly underway again. Fierce Biotech describes 2026 as a strong M&A year after a wave of large deals in March, with seven deals over 1 bn. USD in 12 days and a total value of around 29 bn. USD. Among the examples are Merck/Terns at 6.7 bn. USD, Gilead/Ouro at approx. 2.2 bn. USD and Novartis/Excellergy at 2.0 bn. USD. My simple interpretation: Nykode is still early and needs to prove more in Abili-T, but the market now shows that large pharma companies are actually willing to pay a lot for promising early-stage biotech when they see clear biological signal and strategic value. This does not make Nykode a sure acquisition case, but it makes the case easier to take seriously.
·7 t sittenGood comment, ABG's recommendation of 4.41 appears modest compared to what is being presented now + upcoming triggers. However, I still don't think NYKD is an acquisition candidate yet, as the major owners who have been quiet for a long time probably expect a much higher return when the time comes.
·12 t sittenvery little volume here. This should be more popular?- 2 päivää sitten2 päivää sitten
·1 päivä sitten · MuokattuTo understand more, I ran it through AI (Claude). Instead of sitting with the summary myself, I'm sharing here what this means: These are Phase 1 data from Nykode's VB-C-03 study – here's what it means in practice: What the study tests The cancer vaccine abi-suva combined with pembrolizumab (Keytruda) in patients with HPV16-positive head and neck cancer that has recurred or spread. The important findings All patients in the 6mg and 9mg doses showed a strong T-cell response – the immune system is activated and attacks the cancer cells. The response was rapid, strong, and durable. TCR sequencing shows that the vaccine both reactivates existing immune response and creates entirely new T-cell clones. ORR of 38.5% – almost 4 out of 10 patients responded clinically. This is biological proof that the vaccine does what it's supposed to. It's not just about tumors shrinking – it shows that the immune system actually learns to recognize and attack cancer cells. It is the foundation for Phase 2. This is exactly the type of data needed to proceed to Phase 2 with credibility. The presentation on Tuesday 21. April at AACR in San Diego is a potential stock driver – this is where these data are presented to the world's leading cancer researchers. - ·2 päivää sittenFrom Medwatch.no: – We are a bit ahead of the plans we presented in August, says Nykode Therapeutics director Michael Engsig to MedWatch. The company gets a thumbs up in Europe for the cancer vaccine study. https://medwatch.no/nyheter/legemidler_biotek/article19210999.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
54 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
31,90%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenNykode continues to deliver small, but important data points: In VB-C-03, 10 out of 10 evaluable patients in the 6 mg and 9 mg groups achieved an HPV16-specific immune response. This strengthens the impression that abi-suva not only looks good on paper, but actually awakens the immune system as a cancer vaccine should. At the same time, something important is happening in the market: biotech M&A is clearly underway again. Fierce Biotech describes 2026 as a strong M&A year after a wave of large deals in March, with seven deals over 1 bn. USD in 12 days and a total value of around 29 bn. USD. Among the examples are Merck/Terns at 6.7 bn. USD, Gilead/Ouro at approx. 2.2 bn. USD and Novartis/Excellergy at 2.0 bn. USD. My simple interpretation: Nykode is still early and needs to prove more in Abili-T, but the market now shows that large pharma companies are actually willing to pay a lot for promising early-stage biotech when they see clear biological signal and strategic value. This does not make Nykode a sure acquisition case, but it makes the case easier to take seriously.·7 t sittenGood comment, ABG's recommendation of 4.41 appears modest compared to what is being presented now + upcoming triggers. However, I still don't think NYKD is an acquisition candidate yet, as the major owners who have been quiet for a long time probably expect a much higher return when the time comes.
- ·12 t sittenvery little volume here. This should be more popular?
- 2 päivää sitten2 päivää sitten·1 päivä sitten · MuokattuTo understand more, I ran it through AI (Claude). Instead of sitting with the summary myself, I'm sharing here what this means: These are Phase 1 data from Nykode's VB-C-03 study – here's what it means in practice: What the study tests The cancer vaccine abi-suva combined with pembrolizumab (Keytruda) in patients with HPV16-positive head and neck cancer that has recurred or spread. The important findings All patients in the 6mg and 9mg doses showed a strong T-cell response – the immune system is activated and attacks the cancer cells. The response was rapid, strong, and durable. TCR sequencing shows that the vaccine both reactivates existing immune response and creates entirely new T-cell clones. ORR of 38.5% – almost 4 out of 10 patients responded clinically. This is biological proof that the vaccine does what it's supposed to. It's not just about tumors shrinking – it shows that the immune system actually learns to recognize and attack cancer cells. It is the foundation for Phase 2. This is exactly the type of data needed to proceed to Phase 2 with credibility. The presentation on Tuesday 21. April at AACR in San Diego is a potential stock driver – this is where these data are presented to the world's leading cancer researchers.
- ·2 päivää sittenFrom Medwatch.no: – We are a bit ahead of the plans we presented in August, says Nykode Therapeutics director Michael Engsig to MedWatch. The company gets a thumbs up in Europe for the cancer vaccine study. https://medwatch.no/nyheter/legemidler_biotek/article19210999.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 500 | - | - | ||
| 656 | - | - | ||
| 2 251 | - | - | ||
| 2 645 | - | - | ||
| 4 044 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
54 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
1,00 NOK/osake
Viimeisin osinko
31,90%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sittenNykode continues to deliver small, but important data points: In VB-C-03, 10 out of 10 evaluable patients in the 6 mg and 9 mg groups achieved an HPV16-specific immune response. This strengthens the impression that abi-suva not only looks good on paper, but actually awakens the immune system as a cancer vaccine should. At the same time, something important is happening in the market: biotech M&A is clearly underway again. Fierce Biotech describes 2026 as a strong M&A year after a wave of large deals in March, with seven deals over 1 bn. USD in 12 days and a total value of around 29 bn. USD. Among the examples are Merck/Terns at 6.7 bn. USD, Gilead/Ouro at approx. 2.2 bn. USD and Novartis/Excellergy at 2.0 bn. USD. My simple interpretation: Nykode is still early and needs to prove more in Abili-T, but the market now shows that large pharma companies are actually willing to pay a lot for promising early-stage biotech when they see clear biological signal and strategic value. This does not make Nykode a sure acquisition case, but it makes the case easier to take seriously.·7 t sittenGood comment, ABG's recommendation of 4.41 appears modest compared to what is being presented now + upcoming triggers. However, I still don't think NYKD is an acquisition candidate yet, as the major owners who have been quiet for a long time probably expect a much higher return when the time comes.
- ·12 t sittenvery little volume here. This should be more popular?
- 2 päivää sitten2 päivää sitten·1 päivä sitten · MuokattuTo understand more, I ran it through AI (Claude). Instead of sitting with the summary myself, I'm sharing here what this means: These are Phase 1 data from Nykode's VB-C-03 study – here's what it means in practice: What the study tests The cancer vaccine abi-suva combined with pembrolizumab (Keytruda) in patients with HPV16-positive head and neck cancer that has recurred or spread. The important findings All patients in the 6mg and 9mg doses showed a strong T-cell response – the immune system is activated and attacks the cancer cells. The response was rapid, strong, and durable. TCR sequencing shows that the vaccine both reactivates existing immune response and creates entirely new T-cell clones. ORR of 38.5% – almost 4 out of 10 patients responded clinically. This is biological proof that the vaccine does what it's supposed to. It's not just about tumors shrinking – it shows that the immune system actually learns to recognize and attack cancer cells. It is the foundation for Phase 2. This is exactly the type of data needed to proceed to Phase 2 with credibility. The presentation on Tuesday 21. April at AACR in San Diego is a potential stock driver – this is where these data are presented to the world's leading cancer researchers.
- ·2 päivää sittenFrom Medwatch.no: – We are a bit ahead of the plans we presented in August, says Nykode Therapeutics director Michael Engsig to MedWatch. The company gets a thumbs up in Europe for the cancer vaccine study. https://medwatch.no/nyheter/legemidler_biotek/article19210999.ece
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 500 | - | - | ||
| 656 | - | - | ||
| 2 251 | - | - | ||
| 2 645 | - | - | ||
| 4 044 | - | - |
Välittäjätilasto
Dataa ei löytynyt